文献速递前列腺癌

晚期前列腺癌及同源重组修复基因改变的流行病学系统综述

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
PubMed 文献 · J Urol · 2020-12-17

本文系统综述了2009年1月至2019年5月发表的真实世界证据,评估转移性去势敏感前列腺癌(mCSPC)、非转移性去势抵抗前列腺癌(nmCRPC)和转移性去势抵抗前列腺癌(mCRPC)的全球流行病学及同源重组修复基因改变(HRRm)的患病率和预后影响。共筛选4732篇文献,最终纳入22篇相关出版物。结果显示nmCRPC和mCRPC的患病率分别为前列腺癌病例的1.1%-12.3%和1.2%-2.1%,mCRPC中HRRm以BRCA2最为常见(胚系3.3%-6.0%,体细胞5.0%-15.1%),HRRm患者临床结局与非携带者不同。

要点

  • nmCRPC占前列腺癌病例的1.1%-12.3%,mCRPC占1.2%-2.1%。
  • mCRPC中BRCA2胚系突变率为3.3%-6.0%,体细胞突变率为5.0%-15.1%。
  • HRRm患者临床结局与非携带者不同,但需更多真实世界数据验证。

核心结论

  • 已发表的真实世界证据中,关于晚期前列腺癌及mCRPC以外HRRm流行病学的数据稀疏。
  • mCRPC中HRRm(尤其是BRCA2)的数据与PARP抑制剂临床试验数据一致。
  • 真实世界证据提示mCRPC中HRRm患者与非携带者的临床结局不同。

研究设计与样本

  • 系统文献综述,检索2009年1月至2019年5月发表的真实世界证据。
  • 系统筛选4732篇论文,最终纳入22篇相关出版物进行分析。

主要发现

  • 6篇出版物报告了晚期前列腺癌的全球流行病学,nmCRPC患病率为前列腺癌病例的1.1%-12.3%,mCRPC为1.2%-2.1%,未捕获mCSPC患病率。
  • mCRPC中HRRm患病率最高的是BRCA2,胚系为3.3%-6.0%,体细胞为5.0%-15.1%。
  • 5篇出版物报告了HRRm在晚期前列腺癌中的预后影响。

临床怎么用

  • 对于mCRPC患者,可考虑进行HRRm检测(尤其是BRCA2)以指导治疗决策。
  • 临床实践中应关注HRRm状态对mCRPC患者预后的潜在影响。
  • 需结合真实世界数据与临床试验数据综合评估PARP抑制剂的应用。

局限性

  • 已发表的真实世界证据有限,尤其是mCSPC和nmCRPC的HRRm数据稀疏。
  • 纳入研究多为mCRPC,其他疾病阶段的流行病学数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the global epidemiology of metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC). Additionally, to assess the prevalence of homologous recombination repair gene alterations (HRRm) and their prognostic impact in advanced disease setting. MATERIALS AND METHODS: A systematic literature review of real-world evidence published from January 2009 through May 2019 was conducted to assess global epidemiology and clinical practice trends for mCSPC, nmCRPC, mCRPC and HRRm; 4,732 papers were systematically screened for inclusion. Ten conference proceedings from 2014 through 2019 were reviewed. RESULTS: Of the screened articles 22 relevant publications were identified for this paper. Six publications reported global epidemiology of advanced prostate cancer. The prevalence of nmCRPC was estimated as 1.1% to 12.3% of prostate cancer cases and for mCRPC 1.2% to 2.1% of prostate cancer cases. No mCSPC prevalence was captured. Sixteen publications investigated HRRm prevalence in advanced prostate cancer with the majority conducted in mCRPC assessed using next-generation sequencing of tissue and germline samples. In mCRPC, the highest prevalence HRRm in both germline (3.3%-6.0%) and somatic (5.0%-15.1%) was BRCA2. Five publications reported the prognostic impact of HRRm in advanced prostate cancer. CONCLUSIONS: Published real-world evidence quantifying the prevalence of advanced prostate cancer and HRRm beyond mCRPC is sparse. Published data on HRRm, specifically BRCA2, are consistent with published clinical trial data for poly (ADP-ribose) polymerase inhibitors in mCRPC. In mCRPC, real-world evidence suggests that patients with HRRm have different clinical outcomes to noncarriers. More data are needed to better understand real-world patient segmentation and clinical outcomes for biomarkers given increasing interest in profiling.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Shore N, Oliver L, Shui I, et al. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations. J Urol. 2020. PMID: 33332152. doi:10.1097/JU.0000000000001570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。